$TECX
Tectonic Therapeutic, Inc. Stock $tecx

$tecx Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000119312518325511 Filed on November 13, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.870M	$3.000M	$960.0K
YoY Change	298.97%	212.5%
% of Gross Profit
Research & Development	$12.81M	$9.232M	$5.410M
YoY Change	97.99%	70.65%
% of Gross Profit
Depreciation & Amortization	$180.0K	$130.0K	$10.00K
YoY Change	800.0%	1200.0%
% of Gross Profit
Operating Expenses	$16.68M	$12.23M	$6.370M
YoY Change	124.5%	92.03%
Operating Profit		-$12.23M
YoY Change
Interest Expense	$660.0K	$640.0K	-$70.00K
YoY Change	-512.5%	-1014.29%
% of Operating Profit
Other Income/Expense, Net	$0.00	$641.0K	-$10.00K
YoY Change	-100.0%	-6510.0%
Pretax Income	-$16.02M	-$11.59M	-$6.440M
YoY Change	110.79%	79.97%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$16.02M	-$11.59M	-$6.440M
YoY Change	110.79%	79.98%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$668.9K	-$487.8K	-$288.7K
COMMON SHARES
Basic Shares Outstanding	23.96M shares	23.94M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.3M	$138.6M
YoY Change
Cash & Equivalents	$126.3M	$138.6M	$903.0K
Short-Term Investments
Other Short-Term Assets	$795.0K	$469.0K
YoY Change	1225.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$130.0M	$140.1M
YoY Change	1961.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.634M	$2.306M
YoY Change	654.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$825.0K	$888.0K
YoY Change	126.03%
Total Long-Term Assets	$3.459M	$3.194M
YoY Change	384.45%
TOTAL ASSETS
Total Short-Term Assets	$130.0M	$140.1M
Total Long-Term Assets	$3.459M	$3.194M
Total Assets	$133.5M	$143.3M
YoY Change	1800.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.784M	$1.582M
YoY Change	428.27%
Accrued Expenses	$7.822M	$3.845M
YoY Change	272.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.61M	$5.427M
YoY Change	304.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$700.0K	$700.0K
YoY Change	40.0%
Total Long-Term Liabilities	$700.0K	$700.0K
YoY Change	40.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.61M	$5.427M
Total Long-Term Liabilities	$700.0K	$700.0K
Total Liabilities	$11.30M	$6.163M
YoY Change	208.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.74M	-$55.72M
YoY Change	205.61%
Common Stock	$193.9M	$192.8M
YoY Change	57104.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$122.2M	$137.1M
YoY Change
Total Liabilities & Shareholders Equity	$133.5M	$143.3M
YoY Change	1800.87%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$16.02M	-$11.59M	-$6.440M
YoY Change	110.79%	79.98%
Depreciation, Depletion And Amortization	$180.0K	$130.0K	$10.00K
YoY Change	800.0%	1200.0%
Cash From Operating Activities	-$11.44M	-$11.98M	-$3.100M
YoY Change	29.71%	286.45%
INVESTING ACTIVITIES
Capital Expenditures	-$490.0K	-$920.0K	-$240.0K
YoY Change	512.5%	283.33%
Acquisitions
YoY Change
Other Investing Activities		-$280.0K	$0.00
YoY Change
Cash From Investing Activities	-$230.0K	-$1.200M	-$240.0K
YoY Change	187.5%	400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-140.0K	-3.250M	-40.00K
YoY Change	-101.0%	8025.0%
NET CHANGE
Cash From Operating Activities	-11.44M	-11.98M	-3.100M
Cash From Investing Activities	-230.0K	-1.200M	-240.0K
Cash From Financing Activities	-140.0K	-3.250M	-40.00K
Net Change In Cash	-11.81M	-16.43M	-3.380M
YoY Change	-332.94%	386.09%
FREE CASH FLOW
Cash From Operating Activities	-$11.44M	-$11.98M	-$3.100M
Capital Expenditures	-$490.0K	-$920.0K	-$240.0K
Free Cash Flow	-$10.95M	-$11.06M	-$2.860M
YoY Change	25.29%	286.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	469000
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	888000
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2306000
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19941000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	184033	shares
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23955870	shares
CY2017Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	10000000
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	903000
CY2017Q3	avro	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3845000
CY2018Q3	us-gaap	Assets Current AssetsCurrent	140078000
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	200000
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	192825000
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1582000
CY2018Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	177000
CY2018Q3	us-gaap	Assets Assets	143272000
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138577000
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138577000
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23758898	shares
CY2018Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2812281	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23942929	shares
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	2000
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	736000
CY2018Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	396000
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1329000
CY2018Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	8245000
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5427000
CY2018Q3	us-gaap	Liabilities Liabilities	6163000
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	143272000
CY2018Q3	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	10000000
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	460000
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1501000
CY2018Q3	us-gaap	Prepaid Rent PrepaidRent	99000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2506000
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55718000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.42
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527000
CY2017Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	9000
CY2017Q4	us-gaap	Prepaid Rent PrepaidRent	122000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	394000
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	371000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	794000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2625000
CY2017Q4	us-gaap	Liabilities Liabilities	3657000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7022000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	390636	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.82
CY2017Q4	us-gaap	Assets Assets	7022000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5963000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5963000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	126000
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1957839	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	51000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2305173	shares
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9873128	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2581474	shares
CY2017Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	8418149	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.59
CY2018Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	92454000
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	137109000
CY2018Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	63491857	shares
CY2018Q3	avro	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAggregateIntrinsicValue	72513000
CY2018Q3	avro	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	1724000
CY2018Q3	avro	Initial Public Offering Costs In Accrued Liabilities InitialPublicOfferingCostsInAccruedLiabilities	155000
CY2018Q3	avro	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2018Q3	avro	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvested	1564783	shares
CY2018Q3	avro	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageExercisePrice	5.53
CY2018Q3	avro	Prepaid Development Costs Current PrepaidDevelopmentCostsCurrent	537000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5357000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2098000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	6308000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	339000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	464000
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	60000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	365000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	500000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	349000
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	345000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	909000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	66000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	500000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	141000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23474000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.42
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	276301	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1034961	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.78
CY2017Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	26500000
CY2017Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	34783832	shares
CY2017Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	26500000
CY2017Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	34783832	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3427000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-23135000
CY2017Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	34972535	shares
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	35000
CY2017Q4	avro	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	831000
CY2017Q4	avro	Prepaid Development Costs Current PrepaidDevelopmentCostsCurrent	163000
CY2018Q1	us-gaap	Security Deposit SecurityDeposit	209000
CY2018Q1	avro	Operating Lease Annual Increase In Rental Percentage OperatingLeaseAnnualIncreaseInRentalPercentage	0.03	pure
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2420135	pure
CY2018Q1	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-01-31
CY2018Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	842000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	110000
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	13000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	36000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4454000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11052000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	28000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	28000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.01
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-93000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2230000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1910000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-96000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-302000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3404000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7556000
	us-gaap	Net Income Loss NetIncomeLoss	-11052000
	us-gaap	Operating Expenses OperatingExpenses	10956000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	20000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1339000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	104168000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10956000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	19000
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	44000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	302000
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	3448000
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	47000
	us-gaap	Profit Loss ProfitLoss	-11052000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8726000
	us-gaap	Share Based Compensation ShareBasedCompensation	110000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0189	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.14
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	43000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8473	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2216180	shares
	avro	Upfront License Fees UpfrontLicenseFees	0
	avro	Upfront Fees UpfrontFees	0
	avro	Deferred Rent Expense DeferredRentExpense	134000
	avro	Issuance Of Warrants In Connection With Debt IssuanceOfWarrantsInConnectionWithDebt	18000
	avro	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-11099000
	avro	License Maintenance Fees LicenseMaintenanceFees	0
	avro	Accretion Of Issuance Costs Related To Redeemable Convertible Preferred Stock AccretionOfIssuanceCostsRelatedToRedeemableConvertiblePreferredStock	47000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1117000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	33000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	236000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Type DocumentType	10-Q
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	196000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.28
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Concentrations of Credit Risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The Company has no significant <font style="WHITE-SPACE: nowrap">off-balance</font> sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash and cash equivalents in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p> </div>
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	132614000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30340000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	196000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001681087
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	130000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y5M1D
	dei	Entity Registrant Name EntityRegistrantName	AVROBIO, INC.
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	162000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-1629000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7281000
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	235000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	829000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1509000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1138000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	259000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	383000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1038000
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2017-02-28
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-773000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1598000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	160426000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26214000
	us-gaap	Net Income Loss NetIncomeLoss	-30340000
	us-gaap	Operating Expenses OperatingExpenses	29567000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29567000
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	58258000
	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	2243000
	us-gaap	Profit Loss ProfitLoss	-30340000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22286000
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1117000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M25D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0273	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	92268	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	39000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8342	pure
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3000000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	646000
	avro	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-6441000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	922878	shares
	dei	Trading Symbol TradingSymbol	AVRO
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, stock-based compensation expense, the valuation of equity and derivative instruments and the recoverability of the Company’s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9945538	shares
	avro	Upfront License Fees UpfrontLicenseFees	0
	avro	Upfront Fees UpfrontFees	0
	avro	Deferred Rent Expense DeferredRentExpense	-63000
	avro	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-32583000
	avro	License Maintenance Fees LicenseMaintenanceFees	0
	avro	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAndExpirationsInPeriod	0	shares
	avro	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P9Y3D
	avro	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y6M10D
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-71000
	us-gaap	Net Income Loss NetIncomeLoss	-6441000
	us-gaap	Operating Expenses OperatingExpenses	6370000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6370000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	14000
	avro	Purchases Of Property And Equipment Paid For By Landlord PurchasesOfPropertyAndEquipmentPaidForByLandlord	842000
	avro	Property And Equipment Held For Sale PropertyAndEquipmentHeldForSale	19000
	avro	Accretion Of Issuance Costs Related To Redeemable Convertible Preferred Stock AccretionOfIssuanceCostsRelatedToRedeemableConvertiblePreferredStock	2240000
	avro	Payment Of Dilution Liability PaymentOfDilutionLiability	2000000
	avro	Ipo Issuance Costs Included In Accrued Expenses IpoIssuanceCostsIncludedInAccruedExpenses	155000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M8D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	550000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11591000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5411000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0188	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8388	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2263195	shares
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	641000
	us-gaap	Net Income Loss NetIncomeLoss	-11591000
	us-gaap	Operating Expenses OperatingExpenses	12232000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12232000
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	5000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9232000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0281	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7915	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23747141	shares
	avro	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-11591000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	46000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6441000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.85
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	6000
	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-58000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	959000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000

Files In Submission

Name	View Source	Status
0001193125-18-325511-index-headers.html	Edgar Link	pending
0001193125-18-325511-index.html	Edgar Link	pending
0001193125-18-325511.txt	Edgar Link	pending
0001193125-18-325511-xbrl.zip	Edgar Link	pending
avro-20180930.xml	Edgar Link	completed
avro-20180930.xsd	Edgar Link	pending
avro-20180930_cal.xml	Edgar Link	unprocessable
avro-20180930_def.xml	Edgar Link	unprocessable
avro-20180930_lab.xml	Edgar Link	unprocessable
avro-20180930_pre.xml	Edgar Link	unprocessable
d624778d10q.htm	Edgar Link	pending
d624778dex311.htm	Edgar Link	pending
d624778dex312.htm	Edgar Link	pending
d624778dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TECX
Tectonic Therapeutic, Inc. Stock $tecx

2018 Q4 Form 10-Q Financial Statement

#000119312518325511 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TECX Tectonic Therapeutic, Inc. Stock $tecx

2018 Q4 Form 10-Q Financial Statement

#000119312518325511 Filed on November 13, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TECX
Tectonic Therapeutic, Inc. Stock $tecx